StreetInsider.com News Articles

Form ARS Glucotrack, Inc. For: Dec 31

Fri, 17 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260717/26784986.html

Form ARS Glucotrack, Inc. For: Dec 31

Fri, 17 Jul 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260717/26784986.html

Form DEF 14A Glucotrack, Inc. For: Jul 17

Fri, 17 Jul 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260717/26784870.html

Form DEF 14A Glucotrack, Inc. For: Jul 17

Fri, 17 Jul 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260717/26784870.html

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Conve

Fri, 17 Jul 2026 13:20:31 -0400

NEW YORK, July 17, 2026 (GLOBE NEWSWIRE) -- E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it served as exclusive financial advisor in the strategic business combination between Glucotrack, Inc. (Nasdaq: GCTK) and Lōkahi Therapeutics, and as exclusive placement agent for a concurrent convertible note financing of approximately $5.7 million to support the combined company's post-closing growth.

The transaction establishes a publicly traded, capital-efficient healthcare platform, pairing Lōkahi Therapeutics' AI-driven asset sourcing and development capabilities with Glucotrack's Nasdaq listing to create a scalable framework for

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Conve

Fri, 17 Jul 2026 13:20:31 -0400

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million C

Fri, 17 Jul 2026 13:20:00 -0400

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million C

Fri, 17 Jul 2026 13:20:00 -0400

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million C

Fri, 17 Jul 2026 13:20:00 -0400

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million C

Fri, 17 Jul 2026 13:20:00 -0400

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million C

Fri, 17 Jul 2026 13:20:00 -0400

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million C

Fri, 17 Jul 2026 13:20:00 -0400

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million C

Fri, 17 Jul 2026 13:20:00 -0400

E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million C

Fri, 17 Jul 2026 13:20:00 -0400

Glucotrack completes bridge financing after Lōkahi merger

Fri, 17 Jul 2026 08:06:26 -0400

Glucotrack, Inc. (NASDAQ: GCTK) has completed a bridge financing following its business combination with Lōkahi Therapeutics, the company announced July 17, 2026, based in Rutherford, N.J.

E.F. Hutton & Co. served as exclusive financial advisor and placement agent for the bridge financing. The firm will continue to advise the company as it evaluates additional financing opportunities.

The business combination between Glucotrack and Lōkahi was announced July 14, 2026. Lōkahi is a clinical-stage biopharmaceutical company focused on non-opioid biologic therapies.

"The successful completion of this bridge financing represents an important step in our broader strategic plan," said Erik Emerson, Chief Executive Officer of Glucotrack.

Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Ini